Breaking News: Biogen’s Alzheimer's drug sales beat expectations in Q1

Biogen saw a surprise jump in sales of its new Alzheimer's disease drug in early 2024, beating analyst estimates for Leqembi in the first quarter.    

The rollout of Leqembi has picked up steam, surprising analysts and driving the company's shares up in pre-market trading. But the company says don't expect to see big revenue growth in 2024. Here's why.

‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ 

April 24, 2024

Breaking News

Biogen's Alzheimer's drug sales beat expectations in Q1 The rollout of Leqembi has picked up steam, surprising analysts and driving the company's shares up in pre-market trading. But the company says don't expect to see big revenue growth in 2024. Here's why. Read Full Article

Related News

Lawsuit over Boston stadium renovation moves forward

It's on Mayor Wu to fix North End outdoor dining spat: Editorial

Biogen makes good on vow to reduce headcount

Former Biogen exec tapped for top spot at Dyne

Biogen has four approvals, but still fighting for revenue growth

View as a Web Page

Unsubscribe | Manage Preferences All rights reserved. © Boston Business Journal Email sent by Boston Business Journal 70 Franklin Street, 8th Floor Boston, MA 02110 USA